References
- 1. Food and Drug Administration, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services, Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs, October 2002; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079239.pdf; last access date July 9, 2017.
- 2. International Conference on Harmonisation, Harmonised Tripartite Guideline: Immunotoxicity Studies for Human Pharmaceuticals S8, May 2005; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002851.pdf; last access date July 9, 2017.
- 3. M. Collinge, L. A. Burns-Naas, G. J. Chellman, T. T. Kawabata, W. J. Komocsar, J. R. Piccotti, J. Shenton and D. Wierda, Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations, J. Immunotoxicol. 9 (2012) 210-230; https://doi.org/10.3109/1547691X.2012.661486
- 4. B. Blaszczyk, W. Lason and S. J. Czuczwar, Antiepileptic drugs and adverse skin reactions: An update, Pharmacol. Rep. 67 (2015) 426-434; https://doi.org/10.1016/j.pharep.2014.11.009
- 5. T. Shimada, T. Takemiya, H. Sugiura and K. Yamagata, Role of inflammatory mediators in the pathogenesis of epilepsy, Mediators Inflam. 2014 (2014), Article 901902 (8 pages); https://doi.org/10.1155/2014/901902
- 6. E. E. de Vries, B. van den Munckhof, K. P. Braun, A. van Royen-Kerkhof, W. de Jager and F. E. Jansen, Inflammatory mediators in human epilepsy: A systematic review and meta-analysis, Neurosci. Biobehav. Rev. 63 (2016) 177-190; https://doi.org/10.1016/j.neubiorev.2016.02.007
- 7. J. T. Jarvela, F. R. Lopez-Picon, A. Plysjuk, S. Ruohonen and I. E. Holopainen, Temporal profiles of age-dependent changes in cytokine mRNA expression and glial cell activation after status epilepticus in postnatal rat hippocampus, J. Neuroinflammation 8 (2011), Article 29 (12 pages); https://doi.org/10.1186/1742-2094-8-29
- 8. R. Pacifici, L. Paris, S. Di Carlo, A. Bacosi, S. Pichini and P. Zuccaro, Cytokine production in blood mononuclear cells from epileptic patients, Epilepsia 36 (1995) 384-387.
- 9. G. De Sarro, D. Rotiroti, M.G. Audino, S. Gratteri and G. Nistico, Effects of interleukin-2 on various models of experimental epilepsy in DBA/2 mice, Neuroimmunomodulation 1 (1994) 361-369.
- 10. N. Basaran, F. Hincal, E. Kansu and A. Ciger, Humoral and cellular immune parameters in untreated and phenytoin-or carbamazepine-treated epileptic patients, Int. J. Immunopharmacol. 16 (1994) 1071-1077.
- 11. A. Basta-Kaim, B. Budziszewska, M. Leskiewicz, M. Kubera, G. Jagla, W. Nowak, S. J. Czuczwar and W. Lason, Effects of new antiepileptic drugs and progabide on the mitogen-induced proliferative activity of mouse splenocytes, Pharmacol. Rep. 60 (2008) 925-932.
- 12. H. Himmerich, S. Bartsch, H. Hamer, R. Mergl, J. Schonherr, C. Petersein, A. Munzer, K. C. Kirkby, K. Bauer and U. Sack, Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro, J. Psychiatr. Res. 47 (2013) 1751-1759; https://doi.org/10.1016/j.jpsychires.2013.07.026
- 13. H. Himmerich, S. Bartsch, H. Hamer, R. Mergl, J. Schonherr, C. Petersein, A. Munzer, K. C. Kirkby, K. Bauer and U. Sack, Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-Cd40-stimulated blood in vitro, Oxid. Med. Cell Longev. 2014 (2014) article 806162 (11 pages); https://doi.org/10.1155/2014/806162
- 14. K. S. Prabhavalkar, N. B. Poovanpallil and L. K. Bhatt, Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer, Front. Pharmacol. 6 (2015) article 242 (11 pages); https://doi.org/10.3389/fphar.2015.00242
- 15. X. Q. Wang, B. Lv, H. F. Wang, X. Zhang, S. Y. Yu, X. S. Huang, J. T. Zhang, C. L. Tian and S. Y. Lang, Lamotrigine induced DIHS/DRESS: Manifestations, treatment, and outcome in 57 patients, Clin. Neurol. Neurosurg. 138 (2015) 1-7; https://doi.org/10.1016/j.clineuro.2015.07.008
- 16. S. Svalheim, U. Mushtaq, M. Mochol, G. Luef, M. Rauchenzauner, S. S. Froland and E. Tauboll, Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine, Acta Neurol. Scand. 127 (2013) 11-15; https://doi.org/10.1111/ane.12044
- 17. M. Fararjeh, M. K. Mohammad, Y. Bustanji, H. Alkhatib and S. Abdalla, Evaluation of immunosuppression induced by metronidazole in Balb/c mice and human peripheral blood lymphocytes, Int. Immunopharmacol. 8 (2008) 341-350; https://doi.org/10.1016/j.intimp.2007.10.018
- 18. E. K. St Louis, Monitoring antiepileptic drugs: a level-headed approach, Curr. Neuropharmacol. 7 (2009) 115-119; https://doi.org/10.2174/157015909788848938
- 19. E. Y. Abu-Rish, V. Kasabri, M. M. Hudaib, S. H. Mashalla, L. H. Al Alawi, K. Tawaha, M. K. Mohammad, Y. S. Mohamed and Y. Bustanji, Evaluation of antiproliferative activity of some traditional anticancer herbal remedies from Jordan, Trop. J. Pharm. Res. 15 (2016) 469-474; https://doi.org/10.4314/tjpr.v15i3.6
- 20. G. Sachs, C. Bowden, J. R. Calabrese, T. Ketter, T. Thompson, R. White and B. Bentley, Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder, Bipolar Disord. 8 (2006) 175-181; https://doi.org/10.1111/j.1399-5618.2006.00308.x
- 21. M. F. Cesta, Normal structure, function, and histology of the spleen, Toxicol. Pathol. 34 (2006) 455-465; https://doi.org/10.1080/01926230600867743
- 22. H. Tryphonas, Approaches to detecting immunotoxic effects of environmental contaminants in humans, Environ. Health Perspect. 109 (2001) 877-884.
- 23. R. Schrijvers, L. Gilissen, A. M. Chiriac and P. Demoly, Pathogenesis and diagnosis of delayedtype drug hypersensitivity reactions, from bedside to bench and back, Clin. Transl. Allergy 5 (2015) article 31 (10 pages); https://doi.org/10.1186/s13601-015-0073-8
- 24. M. C. Garcia-Pelayo, V. S. Bachy, D. A. Kaveh and P. J. Hogarth, BALB/c mice display more enhanced BCG vaccine induced Th1 and Th17 response than C57BL/6 mice but have equivalent protection, Tuberculosis (Edinburgh) 95 (2015) 48-53; https://doi.org/10.1016/j.tube.2014.10.012
- 25. E. Kay, L. Gomez-Garcia, A. Woodfin, R. S. Scotland and J. R. Whiteford, Sexual dimorphisms in leukocyte trafficking in a mouse peritonitis model, J. Leukoc. Biol. 98 (2015) 805-817; https://doi.org/10.1189/jlb.3A1214-601RR
- 26. D. J. Naisbitt, J. Farrell, G. Wong, J. P. Depta, C. C. Dodd, J. E. Hopkins, C. A. Gibney, D. W. Chadwick, W. J. Pichler, M. Pirmohamed and B. K. Park, Characterization of drug-specific T cells in lamotrigine hypersensitivity, J. Allergy Clin. Immunol. 111 (2003) 1393-1403.
- 27. E. Beghi and S. Shorvon, Antiepileptic drugs and the immune system, Epilepsia 52 (2011) 40-44; https://doi.org/10.1111/j.1528-1167.2011.03035.x
- 28. J. M. Dwyer and C. Johnson, The use of concanavalin A to study the immunoregulation of human T cells, Clin. Exp. Immunol. 46 (1981) 237-249.
- 29. A. L. Rodríguez-Perea, E. D. Arcia, C. M. Rueda and P. A. Velilla, Phenotypical characterization of regulatory T cells in humans and rodents, Clin. Exp. Immunol. 185 (2016) 281-291; https://doi.org/10.1111/cei.12804
- 30. J. A. Bellanti, Immunology IV: Clinical Applications in Health and Disease, 3rd ed., I Care Press, Bethesda (MD) 2012.
- 31. S. Liimatainen, M. Fallah, E. Kharazmi, A. M. Haapala, J. Isojarvi and J. Peltola, High concentration of immunoglobulin A is associated with temporal lobe epilepsy, Epilepsy Res. 103 (2013) 54-61; https://doi.org/10.1016/j.eplepsyres.2012.06.002